In the recent first-in-human, multicenter, Phase I, open-label GARNET trial (NCT02715284), dostarlimab monotherapy showed promising antitumor activity in recurrent or advanced NSCLC across various PD-L1 expression subgroups and an acceptable safety profile, with an overall response rate (ORR) of 26.9% (n = 18/67)11. The gene discussed is CD274; the disease is non-small cell lung carcinoma.